entity_type large_string | slug large_string | title large_string | type large_string | top_company large_string | compiled_at large_string | landscape_total_views_7d float64 | landscape_active_orgs_7d float64 | phase large_string | mechanism large_string | originator large_string | indication_count float64 | fda_approval_count float64 | ct_trial_count float64 | research_attention_rank float64 | research_views_7d float64 | research_unique_orgs float64 | research_trend_pct float64 | investment_status large_string | ticker large_string | exchange large_string | total_raised large_string | latest_round large_string | watchlist_total_views_7d float64 | watchlist_drug_count float64 | watchlist_top_drug large_string |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
indication | obesity | Obesity | indication | Eli Lilly and Company (88.71) | 2026-06-12T10:43:48Z | 497 | 71 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | null | null | null | null |
drug | 710-go | 710-GO | drug | null | 2026-06-05T19:43:25Z | null | null | Phase 1 | Melanocortin MC4 receptor agonist; Melanocortin MC3 receptor agonist | Endevica Bio Inc | 1 | 0 | 0 | 5,812 | 0 | 0 | null | null | null | null | null | null | null | null | null |
drug | abbv-295 | ABBV-295 | drug | null | 2026-06-05T19:43:31Z | null | null | Phase 1 | Adrenomedullin receptor agonist; Amylin receptor agonist | Gubra A/S | 1 | 0 | 3 | 1,314 | 2 | 2 | 0 | null | null | null | null | null | null | null | null |
drug | abp2111-na | ABP2111-Na | drug | null | 2026-06-05T19:43:35Z | null | null | Phase 2 | AB Pharma Ltd | 2 | 0 | 0 | 5,812 | 0 | 0 | null | null | null | null | null | null | null | null | null | |
drug | accg-2671 | ACCG-2671 | drug | null | 2026-06-05T19:43:38Z | null | null | Phase 1 | Amylin receptor agonist; Calcitonin receptor agonist | Structure Therapeutics Inc | 1 | 0 | 0 | 444 | 4 | 2 | 300 | null | null | null | null | null | null | null | null |
drug | acmopatide | acmopatide | drug | null | 2026-06-07T07:51:54Z | null | null | Phase 2 | Gastric inhibitory polypeptide receptor agonist; Glucagon-like peptide 1 receptor agonist | Carmot Therapeutics Inc | 3 | 0 | 0 | 1,189 | 2 | 1 | 0 | null | null | null | null | null | null | null | null |
drug | ado-09 | ADO-09 | drug | null | 2026-06-05T19:43:44Z | null | null | Phase 2 | Insulin ligand; Amylin receptor agonist; Insulin receptor agonist | Adocia SA | 2 | 0 | 0 | 5,812 | 0 | 0 | null | null | null | null | null | null | null | null | null |
drug | aleniglipron | aleniglipron | drug | null | 2026-06-07T07:51:57Z | null | null | Phase 2 | Glucagon-like peptide 1 receptor agonist | Structure Therapeutics Inc | 2 | 0 | 3 | 3,720 | 1 | 1 | -80 | null | null | null | null | null | null | null | null |
drug | alg-055009 | ALG-055009 | drug | null | 2026-06-05T19:43:50Z | null | null | Phase 2 | Thyroid hormone receptor beta agonist | Aligos Therapeutics Inc | 4 | 0 | 0 | 2,019 | 2 | 2 | -67 | null | null | null | null | null | null | null | null |
drug | aln-2232 | ALN-2232 | drug | null | 2026-06-05T19:43:54Z | null | null | Phase 2 | ACVR1C gene inhibitor | Alnylam Pharmaceuticals Inc | 1 | 0 | 1 | 691 | 3 | 2 | 200 | null | null | null | null | null | null | null | null |
drug | aln-4324 | ALN-4324 | drug | null | 2026-06-05T19:43:57Z | null | null | Phase 2 | GRB14 gene inhibitor | Alnylam Pharmaceuticals Inc | 2 | 0 | 2 | 146 | 5 | 2 | null | null | null | null | null | null | null | null | null |
drug | alv-100 | ALV-100 | drug | null | 2026-06-05T19:44:00Z | null | null | Phase 2 | Gastric inhibitory polypeptide receptor antagonist; Glucagon-like peptide 1 receptor agonist | Hangzhou Gmax Biopharm Biomedical Engineering Co Ltd | 2 | 0 | 1 | 5,812 | 0 | 0 | null | null | null | null | null | null | null | null | null |
drug | amg-171 | AMG-171 | drug | null | 2026-06-05T19:44:03Z | null | null | Phase 1 | GDF-15 ligand modulator | Amgen Inc | 1 | 0 | 0 | 5,812 | 0 | 0 | null | null | null | null | null | null | null | null | null |
drug | amg-513 | AMG-513 | drug | null | 2026-06-05T19:44:06Z | null | null | Phase 1 | Amgen Inc | 1 | 0 | 1 | 5,812 | 0 | 0 | null | null | null | null | null | null | null | null | null | |
drug | aph-012 | APH-012 | drug | null | 2026-06-05T19:44:13Z | null | null | Phase 2 | Unspecified hormone modulator | Aphaia Pharma AG | 2 | 0 | 0 | 5,812 | 0 | 0 | null | null | null | null | null | null | null | null | null |
drug | aph-01727 | APH-01727 | drug | null | 2026-06-05T19:44:16Z | null | null | Phase 1 | Glucagon-like peptide 1 receptor agonist | ApicHope Pharmaceutical Co Ltd | 2 | 0 | 0 | 2,024 | 2 | 1 | null | null | null | null | null | null | null | null | null |
drug | apitegromab | apitegromab | drug | null | 2026-06-07T07:52:00Z | null | null | Filed | GDF-8 antagonist | Scholar Rock Holding Corp | 7 | 0 | 2 | 5,294 | 1 | 1 | -80 | null | null | null | null | null | null | null | null |
drug | ar-3001 | AR-3001 | drug | null | 2026-06-05T19:44:22Z | null | null | Phase 1 | AriBio Co Ltd | 2 | 0 | 0 | 5,801 | 0 | 0 | null | null | null | null | null | null | null | null | null | |
drug | ard-201 | ARD-201 | drug | null | 2026-06-05T19:44:25Z | null | null | Phase 1 | Taste receptor type 2 agonist; Dipeptidyl peptidase IV inhibitor | Aardvark Therapeutics Inc | 1 | 0 | 0 | 5,812 | 0 | 0 | null | null | null | null | null | null | null | null | null |
drug | aro-alk7 | ARO-ALK7 | drug | null | 2026-06-05T19:44:28Z | null | null | Phase 2 | ACVR1C gene inhibitor | Arrowhead Pharmaceuticals Inc | 1 | 0 | 1 | 573 | 3 | 2 | null | null | null | null | null | null | null | null | null |
drug | aro-inhbe | ARO-INHBE | drug | null | 2026-06-05T19:44:31Z | null | null | Phase 2 | INHBE gene inhibitor | Arrowhead Pharmaceuticals Inc | 1 | 0 | 1 | 252 | 4 | 2 | null | null | null | null | null | null | null | null | null |
drug | asc-30 | ASC-30 (oral, obesity), Ascletis Pharma | drug | null | 2026-06-04T19:45:27Z | null | null | Phase 2 | Glucagon-like peptide 1 receptor agonist | Ascletis Pharma Inc | 2 | 0 | 2 | null | null | null | null | null | null | null | null | null | null | null | null |
drug | asc-30-sc | ASC-30 (sc/once-quarterly/depot, obesity), Ascletis Pharma | drug | null | 2026-06-04T19:54:30Z | null | null | Phase 2 | Glucagon-like peptide 1 receptor agonist | Ascletis Pharma Inc | 1 | 0 | 2 | 5,812 | 0 | 0 | null | null | null | null | null | null | null | null | null |
drug | asc-30 | ASC-30 (oral, obesity), Ascletis Pharma | drug | null | 2026-06-05T22:11:11Z | null | null | Phase 2 | Glucagon-like peptide 1 receptor agonist | Ascletis Pharma Inc | 2 | 0 | 2 | null | null | null | null | null | null | null | null | null | null | null | null |
drug | asc-41 | ASC-41 | drug | null | 2026-06-05T19:44:41Z | null | null | Phase 2 | Thyroid hormone receptor beta agonist | Ascletis Pharma Inc | 3 | 0 | 1 | 1,772 | 2 | 1 | 0 | null | null | null | null | null | null | null | null |
drug | asc-47 | ASC-47 | drug | null | 2026-06-05T19:44:44Z | null | null | Phase 1 | Thyroid hormone receptor beta agonist | Gannex Pharma Co Ltd | 2 | 0 | 0 | 1,413 | 2 | 2 | 100 | null | null | null | null | null | null | null | null |
drug | asct-83 | ASCT-83 | drug | null | 2026-06-05T19:44:47Z | null | null | Phase 1 | Small CTD phosphatase 1 inhibitor; RE1 silencing transcription factor inhibitor | Alcamena Stem Cell Therapeutics LLC | 11 | 0 | 0 | 5,812 | 0 | 0 | null | null | null | null | null | null | null | null | null |
drug | at-247 | AT-247 | drug | null | 2026-06-05T19:44:50Z | null | null | Phase 1 | Insulin receptor agonist; Insulin ligand | Arecor Ltd | 2 | 0 | 0 | 5,812 | 0 | 0 | null | null | null | null | null | null | null | null | null |
drug | at-278 | AT-278 | drug | null | 2026-06-05T19:44:53Z | null | null | Phase 2 | Insulin receptor agonist; Insulin ligand | Arecor Ltd | 3 | 0 | 0 | 5,801 | 0 | 0 | null | null | null | null | null | null | null | null | null |
drug | at-7687 | AT-7687 | drug | null | 2026-06-05T19:44:57Z | null | null | Phase 1 | Gastric inhibitory polypeptide receptor antagonist | Antag Therapeutics Aps | 3 | 0 | 0 | 5,801 | 0 | 0 | null | null | null | null | null | null | null | null | null |
drug | atr-258 | ATR-258 | drug | null | 2026-06-05T19:45:00Z | null | null | Phase 2 | Beta 2 adrenoceptor agonist; Facilitated glucose transporter-4 modulator; Beta-adrenoceptor related kinase-1 stimulator | Atrogi AB | 3 | 0 | 0 | 2,278 | 1 | 1 | null | null | null | null | null | null | null | null | null |
drug | atx-304 | ATX-304 | drug | null | 2026-06-05T19:45:03Z | null | null | Phase 2 | Subtilisin inhibitor; Proprotein convertase PC9 inhibitor; AMP activated protein kinase stimulator | Betagenon AB | 9 | 0 | 0 | 4,271 | 1 | 1 | 0 | null | null | null | null | null | null | null | null |
drug | azd-1043 | AZD-1043 | drug | null | 2026-06-05T19:45:07Z | null | null | Phase 1 | AstraZeneca plc | 1 | 0 | 1 | 5,801 | 0 | 0 | null | null | null | null | null | null | null | null | null | |
drug | azd-6234 | AZD-6234 | drug | null | 2026-06-05T19:45:10Z | null | null | Phase 2 | Amylin receptor agonist | AstraZeneca plc | 1 | 0 | 6 | 5,801 | 0 | 0 | null | null | null | null | null | null | null | null | null |
drug | azd-9550 | AZD-9550 | drug | null | 2026-06-05T19:45:13Z | null | null | Phase 2 | Glucagon-like peptide 1 receptor agonist; Glucagon receptor agonist | AstraZeneca plc | 1 | 0 | 4 | 411 | 4 | 3 | -33 | null | null | null | null | null | null | null | null |
drug | bc-006-basecure-therapeutics | BC-006, BaseCure Therapeutics | drug | null | 2026-06-05T19:45:16Z | null | null | Phase 2 | INHBE gene inhibitor | BaseCure Therapeutics Inc | 1 | 0 | 0 | null | null | null | null | null | null | null | null | null | null | null | null |
drug | beinaglutide | beinaglutide | drug | null | 2026-06-07T07:52:03Z | null | null | Launched | Glucagon-like peptide 1 receptor agonist | Shanghai Benemae Pharmaceutical Corp | 4 | 0 | 1 | 5,801 | 0 | 0 | null | null | null | null | null | null | null | null | null |
drug | bge-102 | BGE-102 | drug | null | 2026-06-05T19:45:22Z | null | null | Phase 1 | NACHT LRR PYD domain protein 3 inhibitor | BioAge Labs Inc | 5 | 0 | 0 | 73 | 7 | 1 | 250 | null | null | null | null | null | null | null | null |
drug | bgm-0504-oral | BGM-0504 (oral), BrightGene Bio Medical Technology | drug | null | 2026-06-04T20:47:26Z | null | null | Phase 1 | Gastric inhibitory polypeptide receptor agonist; Glucagon-like peptide 1 receptor agonist | BrightGene Bio-Medical Technology Co Ltd | 1 | 0 | 3 | 4,771 | 1 | 1 | -50 | null | null | null | null | null | null | null | null |
drug | bgm-0504 | BGM-0504 (oral), BrightGene Bio Medical Technology | drug | null | 2026-06-05T19:45:29Z | null | null | Phase 1 | Gastric inhibitory polypeptide receptor agonist; Glucagon-like peptide 1 receptor agonist | BrightGene Bio-Medical Technology Co Ltd | 1 | 0 | 3 | 5,105 | 1 | 1 | -50 | null | null | null | null | null | null | null | null |
drug | bgm-1812 | BGM-1812 | drug | null | 2026-06-05T19:45:32Z | null | null | Phase 1 | Amylin receptor agonist | BrightGene Pharmaceutical (Suzhou) Co Ltd | 1 | 0 | 2 | 3,712 | 1 | 1 | null | null | null | null | null | null | null | null | null |
drug | bi-1356225 | BI-1356225 | drug | null | 2026-06-05T19:45:35Z | null | null | Phase 1 | Boehringer Ingelheim International GmbH | 2 | 0 | 0 | 5,801 | 0 | 0 | null | null | null | null | null | null | null | null | null | |
drug | bi-3006337 | BI-3006337 | drug | null | 2026-06-05T19:45:38Z | null | null | Phase 1 | FGF-21 ligand modulator | Boehringer Ingelheim International GmbH | 4 | 0 | 0 | 1,332 | 2 | 1 | null | null | null | null | null | null | null | null | null |
drug | bi-3034701 | BI-3034701 | drug | null | 2026-06-05T19:45:40Z | null | null | Phase 1 | Gubra A/S | 1 | 0 | 0 | 2,995 | 1 | 1 | -67 | null | null | null | null | null | null | null | null | |
drug | biib-110 | BIIB-110 | drug | null | 2026-06-05T19:45:44Z | null | null | Phase 1 | Activin type-IIB receptor antagonist; GDF-8 antagonist | Alivegen USA Inc | 10 | 0 | 0 | 811 | 3 | 3 | 0 | null | null | null | null | null | null | null | null |
drug | bimagrumab | bimagrumab | drug | null | 2026-06-07T07:52:06Z | null | null | Phase 2 | Activin type-IIA receptor antagonist; Activin type-IIB receptor antagonist | MorphoSys AG | 1 | 0 | 2 | 2,700 | 1 | 1 | -75 | null | null | null | null | null | null | null | null |
drug | bio-101 | BIO-101 | drug | null | 2026-06-05T19:45:50Z | null | null | Phase 3 | Proto-oncogene Mas agonist | BIOPHYTIS SA | 9 | 0 | 0 | 5,801 | 0 | 0 | null | null | null | null | null | null | null | null | null |
drug | bivamelagon | bivamelagon | drug | null | 2026-06-07T07:52:09Z | null | null | Phase 2 | Melanocortin MC4 receptor agonist | LG Chem Ltd | 2 | 0 | 0 | 5,353 | 1 | 1 | -50 | null | null | null | null | null | null | null | null |
drug | bl-001-bloom-science | BL-001, Bloom Science | drug | null | 2026-06-05T19:45:56Z | null | null | Phase 1 | Bloom Science Inc | 4 | 0 | 0 | null | null | null | null | null | null | null | null | null | null | null | null | |
drug | bl-001-bloom-science | BL-001, Bloom Science | drug | null | 2026-06-04T20:49:53Z | null | null | Phase 1 | GABA uptake modulator; Glutamate reuptake modulator | Bloom Science Inc | 4 | 0 | 0 | null | null | null | null | null | null | null | null | null | null | null | null |
drug | bmf-650 | BMF-650 | drug | null | 2026-06-05T19:45:59Z | null | null | Phase 1 | Glucagon-like peptide 1 receptor agonist | Biomea Fusion Inc | 4 | 0 | 1 | 2,256 | 1 | 1 | null | null | null | null | null | null | null | null | null |
drug | bms-986172 | BMS-986172 | drug | null | 2026-06-05T19:46:02Z | null | null | Phase 1 | Insulin sensitizer; N acetylglucosaminyltransferase 2 inhibitor | Bristol Myers Squibb Co | 2 | 0 | 0 | 5,801 | 0 | 0 | null | null | null | null | null | null | null | null | null |
drug | bofanglutide | bofanglutide (sc, type 2 diabetes mellitus/obesity), Gan & Lee Pharmaceuticals/Productos Cientficos | drug | null | 2026-06-05T19:46:06Z | null | null | Phase 3 | Glucagon-like peptide 1 receptor agonist | Gan & Lee Pharmaceuticals Co Ltd | 4 | 0 | 0 | 5,801 | 0 | 0 | null | null | null | null | null | null | null | null | null |
drug | bremelanotide-tirzepatide | bremelanotide + tirzepatide (adjunct, sc, obesity), Palatin Technologies | drug | null | 2026-06-05T19:46:09Z | null | null | Phase 2 | Gastric inhibitory polypeptide receptor agonist; Melanocortin MC4 receptor agonist; Glucagon-like peptide 1 receptor agonist | Palatin Technologies Inc | 1 | 1 | 1 | 5,801 | 0 | 0 | null | null | null | null | null | null | null | null | null |
drug | brenipatide | brenipatide | drug | null | 2026-06-07T07:52:12Z | null | null | Phase 3 | Gastric inhibitory polypeptide receptor agonist; Glucagon-like peptide 1 receptor agonist | Eli Lilly & Co | 12 | 0 | 11 | 41 | 8 | 3 | 300 | null | null | null | null | null | null | null | null |
drug | cagrilintide-semaglutide | cagrilintide + semaglutide (fixed-dose combination/sc, obesity/type 2 diabetes), Novo Nordisk | drug | null | 2026-06-05T19:46:18Z | null | null | Filed | Amylin receptor agonist; Calcitonin receptor agonist; Glucagon-like peptide 1 receptor agonist | Novo Nordisk A/S | 7 | 4 | 0 | null | null | null | null | null | null | null | null | null | null | null | null |
drug | cagrilintide | cagrilintide | drug | null | 2026-06-07T07:52:16Z | null | null | Phase 3 | Amylin receptor agonist | Novo Nordisk A/S | 4 | 0 | 16 | 1,849 | 2 | 2 | null | null | null | null | null | null | null | null | null |
drug | cannabidiol | cannabidiol (hypertension, DehydraTECH), Lexaria Bioscience | drug | null | 2026-06-04T20:59:09Z | null | null | Phase 1 | Cannabinoid receptor agonist | Lexaria Bioscience Corp | 7 | 1 | 105 | null | null | null | null | null | null | null | null | null | null | null | null |
drug | cannabidiol | cannabidiol (hypertension, DehydraTECH), Lexaria Bioscience | drug | null | 2026-06-05T19:46:22Z | null | null | Phase 1 | Cannabinoid receptor agonist | Lexaria Bioscience Corp | 7 | 1 | 105 | null | null | null | null | null | null | null | null | null | null | null | null |
drug | cbl-514 | CBL-514 | drug | null | 2026-06-05T19:46:25Z | null | null | Phase 2 | Bax protein stimulator | Caliway Biopharmaceuticals Co Ltd | 7 | 0 | 2 | 5,801 | 0 | 0 | null | null | null | null | null | null | null | null | null |
drug | cbw-511 | CBW-511 | drug | null | 2026-06-05T19:46:28Z | null | null | Phase 2 | Caliway Biopharmaceuticals Co Ltd | 4 | 0 | 0 | 5,801 | 0 | 0 | null | null | null | null | null | null | null | null | null | |
drug | celastrol | celastrol (oral, obesity/type 2 diabetes/prader-willi syndrome), ERX Pharmaceuticals | drug | null | 2026-06-05T19:46:31Z | null | null | Phase 2 | ERX Pharmaceuticals Inc | 1 | 0 | 1 | 1,073 | 2 | 2 | 0 | null | null | null | null | null | null | null | null | |
drug | cg-0416 | CG-0416 | drug | null | 2026-06-05T19:46:34Z | null | null | Phase 1 | Thyroid hormone receptor beta agonist | Shanghai CureGene Pharmaceutical Co Ltd | 3 | 0 | 0 | 2,970 | 1 | 1 | 0 | null | null | null | null | null | null | null | null |
drug | cgx-926 | CGX-926 | drug | null | 2026-06-05T19:46:37Z | null | null | Phase 1 | Melanocortin MC4 receptor modulator; Melanocortin MC4 receptor agonist | Congruence Therapeutics Inc | 1 | 0 | 0 | 5,801 | 0 | 0 | null | null | null | null | null | null | null | null | null |
drug | cin-109 | CIN-109 | drug | null | 2026-06-05T19:46:41Z | null | null | Phase 1 | GDF-15 ligand modulator | Janssen Research & Development LLC | 1 | 0 | 0 | 5,801 | 0 | 0 | null | null | null | null | null | null | null | null | null |
drug | cin-110 | CIN-110 | drug | null | 2026-06-05T19:46:44Z | null | null | Phase 1 | Peptide YY ligand | J&J Innovative Medicine | 1 | 0 | 0 | 4,573 | 1 | 1 | null | null | null | null | null | null | null | null | null |
drug | cin-209 | CIN-209 | drug | null | 2026-06-05T19:46:47Z | null | null | Discovery | Glucagon-like peptide 1 receptor agonist; GDF-15 ligand modulator | J&J Innovative Medicine | 1 | 0 | 0 | 5,801 | 0 | 0 | null | null | null | null | null | null | null | null | null |
drug | cin-210 | CIN-210 | drug | null | 2026-06-05T19:46:50Z | null | null | Discovery | Glucagon-like peptide 1 receptor agonist; Peptide YY ligand | J&J Innovative Medicine | 1 | 0 | 0 | 5,801 | 0 | 0 | null | null | null | null | null | null | null | null | null |
drug | ck-0045 | CK-0045 | drug | null | 2026-06-05T19:46:53Z | null | null | Phase 2 | IL-22 agonist | Novo Nordisk A/S | 4 | 0 | 0 | 5,801 | 0 | 0 | null | null | null | null | null | null | null | null | null |
drug | cmz-371 | CMZ-371 | drug | null | 2026-06-05T19:46:56Z | null | null | Phase 1 | Gastric inhibitory polypeptide receptor agonist; Glucagon-like peptide 1 receptor agonist | Calibr-Skaggs Institute | 3 | 0 | 0 | 5,801 | 0 | 0 | null | null | null | null | null | null | null | null | null |
drug | conveglipron | conveglipron | drug | null | 2026-06-07T07:52:19Z | null | null | Phase 3 | Glucagon-like peptide 1 receptor agonist | Hangzhou Zhongmei Huadong Pharmaceutical Co Ltd | 2 | 0 | 0 | 5,801 | 0 | 0 | null | null | null | null | null | null | null | null | null |
drug | cor-1389 | COR-1389 | drug | null | 2026-06-05T19:47:03Z | null | null | Phase 1 | CRF-2 receptor agonist | Corteria Pharmaceuticals SAS | 4 | 0 | 0 | 5,801 | 0 | 0 | null | null | null | null | null | null | null | null | null |
drug | cpx-101 | CPX-101 | drug | null | 2026-06-05T19:47:06Z | null | null | Phase 2 | Gastric inhibitory polypeptide receptor antagonist; Glucagon-like peptide 1 receptor agonist | Chia Tai Tianqing (Guangzhou) Pharmaceutical Co Ltd | 1 | 0 | 0 | 5,801 | 0 | 0 | null | null | null | null | null | null | null | null | null |
drug | crb-913 | CRB-913 | drug | null | 2026-06-05T19:47:09Z | null | null | Phase 1 | Cannabinoid CB1 receptor inverse agonist | Jenrin Discovery Inc | 1 | 0 | 1 | 5,801 | 0 | 0 | null | null | null | null | null | null | null | null | null |
drug | cs-0159 | CS-0159 | drug | null | 2026-06-05T19:47:13Z | null | null | Phase 3 | Farnesoid X receptor agonist | Van Andel Institute | 5 | 0 | 3 | 2,882 | 1 | 1 | 0 | null | null | null | null | null | null | null | null |
drug | cu-20401 | CU-20401 | drug | null | 2026-06-05T19:47:16Z | null | null | Phase 2 | Cutia Therapeutics (Wuxi) Co Ltd | 1 | 0 | 0 | 3,713 | 1 | 1 | null | null | null | null | null | null | null | null | null | |
drug | d2-d3-dopamine-receptor-antagonist | D2/D3 dopamine receptor antagonist (oral, gastroparesis/obesity), Neurogastrx | drug | null | 2026-06-05T19:51:42Z | null | null | Phase 2 | Dopamine D3 receptor antagonist; Dopamine D2 receptor antagonist; Glucagon-like peptide 1 receptor agonist | Neurogastrx Inc | 3 | 0 | 0 | null | null | null | null | null | null | null | null | null | null | null | null |
drug | da-1726-monthly | DA-1726 (once-monthly injection, obesity), Dong-T SA/MetaVia/ImmunoForge | drug | null | 2026-06-04T20:50:56Z | null | null | Phase 1 | Glucagon-like peptide 1 receptor agonist; Glucagon receptor agonist; Oxyntomodulin ligand | Dong-A ST Co Ltd | 1 | 0 | 0 | 3,957 | 1 | 1 | null | null | null | null | null | null | null | null | null |
drug | da-1726 | DA-1726 (once-monthly injection, obesity), Dong-T SA/MetaVia/ImmunoForge | drug | null | 2026-06-05T19:47:19Z | null | null | Phase 1 | Glucagon-like peptide 1 receptor agonist; Glucagon receptor agonist; Oxyntomodulin ligand | Dong-A ST Co Ltd | 1 | 0 | 0 | null | null | null | null | null | null | null | null | null | null | null | null |
drug | da-302168s | DA-302168S | drug | null | 2026-06-05T19:47:22Z | null | null | Phase 2 | Chengdu Diao Pharmaceutical Group Co Ltd | 2 | 0 | 0 | 448 | 3 | 1 | null | null | null | null | null | null | null | null | null | |
drug | denatonium-acetate | denatonium acetate monohydrate | drug | null | 2026-06-04T19:45:27Z | null | null | Phase 3 | Taste receptor type 2 agonist | Aardvark Therapeutics Inc | 3 | 0 | 0 | null | null | null | null | null | null | null | null | null | null | null | null |
drug | denatonium-acetate | denatonium acetate monohydrate | drug | null | 2026-06-05T19:47:25Z | null | null | Phase 3 | Taste receptor type 2 agonist | Aardvark Therapeutics Inc | 3 | 20 | 0 | null | null | null | null | null | null | null | null | null | null | null | null |
drug | dr-10624 | DR-10624 | drug | null | 2026-06-05T19:47:28Z | null | null | Phase 2 | FGF-21 ligand modulator; Glucagon receptor agonist; Glucagon-like peptide 1 receptor agonist | Zhejiang Doer Biologics Corp | 7 | 0 | 1 | 371 | 4 | 3 | 33 | null | null | null | null | null | null | null | null |
drug | dw-1022 | DW-1022 | drug | null | 2026-06-05T19:47:32Z | null | null | Phase 1 | Glucagon-like peptide 1 receptor agonist | Raphas Co Ltd | 1 | 0 | 0 | 4,467 | 1 | 1 | null | null | null | null | null | null | null | null | null |
drug | dwp-306001 | DWP-306001 | drug | null | 2026-06-05T19:47:35Z | null | null | Phase 1 | Sodium glucose transporter-2 inhibitor | Daewoong Pharmaceutical Co Ltd | 1 | 0 | 0 | 5,801 | 0 | 0 | null | null | null | null | null | null | null | null | null |
drug | dwrx-5003 | DWRX-5003 | drug | null | 2026-06-05T19:47:38Z | null | null | Phase 1 | Glucagon-like peptide 1 receptor agonist | Daewoong Therapeutics Inc | 2 | 0 | 0 | 4,485 | 1 | 1 | null | null | null | null | null | null | null | null | null |
drug | ecc-4703 | ECC-4703 | drug | null | 2026-06-05T19:47:41Z | null | null | Phase 2 | Thyroid hormone receptor beta agonist | Eccogene (Shanghai) Co Ltd | 3 | 0 | 2 | 4,679 | 1 | 1 | 0 | null | null | null | null | null | null | null | null |
drug | ecnoglutide | ecnoglutide | drug | null | 2026-06-07T07:52:22Z | null | null | Registered | Glucagon-like peptide 1 receptor agonist | Sciwind Biosciences Co Ltd | 5 | 0 | 5 | 3,897 | 1 | 1 | -50 | null | null | null | null | null | null | null | null |
drug | efimosfermin-alfa | efimosfermin alfa | drug | null | 2026-06-05T19:47:47Z | null | null | Phase 3 | FGF-21 ligand modulator | Novartis Pharmaceuticals Corp | 3 | 0 | 5 | 5,432 | 1 | 1 | 0 | null | null | null | null | null | null | null | null |
drug | efinopegdutide | efinopegdutide | drug | null | 2026-06-07T07:52:25Z | null | null | Phase 2 | Glucagon receptor agonist; Glucagon-like peptide 1 receptor agonist; Oxyntomodulin ligand | Hanmi Pharmaceutical Co Ltd | 7 | 0 | 1 | 838 | 3 | 3 | 200 | null | null | null | null | null | null | null | null |
drug | efmedaglutide-alfa | efmedaglutide alfa | drug | null | 2026-06-05T19:47:53Z | null | null | Filed | Glucagon-like peptide 1 receptor agonist | Genexine Co Ltd | 2 | 0 | 0 | 1,192 | 2 | 1 | 100 | null | null | null | null | null | null | null | null |
drug | efocipegtrutide | efocipegtrutide | drug | null | 2026-06-07T07:52:28Z | null | null | Phase 2 | Gastric inhibitory polypeptide receptor agonist; Glucagon-like peptide 1 receptor agonist; Glucagon receptor agonist | Hanmi Pharmaceutical Co Ltd | 10 | 0 | 1 | 1,466 | 2 | 2 | -33 | null | null | null | null | null | null | null | null |
drug | efpegerglucagon | efpegerglucagon | drug | null | 2026-06-07T07:52:31Z | null | null | Phase 2 | Glucagon ligand; Glucagon receptor agonist | Hanmi Pharmaceutical Co Ltd | 5 | 0 | 1 | 808 | 3 | 2 | null | null | null | null | null | null | null | null | null |
drug | efpeglenatide | efpeglenatide | drug | null | 2026-06-07T07:52:35Z | null | null | Filed | Exendin 4 ligand; Glucagon-like peptide 1 receptor agonist | Hanmi Pharmaceutical Co Ltd | 3 | 0 | 0 | 5,089 | 1 | 1 | 0 | null | null | null | null | null | null | null | null |
drug | efsubaglutide-alfa | efsubaglutide alfa | drug | null | 2026-06-05T19:48:06Z | null | null | Launched | Immunoglobulin gamma Fc receptor agonist; Glucagon-like peptide 1 receptor agonist | KPC Pharmaceuticals Inc | 3 | 20 | 3 | 5,801 | 0 | 0 | null | null | null | null | null | null | null | null | null |
drug | elecoglipron | elecoglipron | drug | null | 2026-06-07T07:52:38Z | null | null | Phase 2 | Glucagon-like peptide 1 receptor agonist | Eccogene (Shanghai) Co Ltd | 2 | 0 | 1 | 1,087 | 2 | 2 | -33 | null | null | null | null | null | null | null | null |
drug | eloralintide | eloralintide | drug | null | 2026-06-07T07:52:41Z | null | null | Phase 3 | Amylin receptor agonist | Eli Lilly & Co | 4 | 0 | 9 | 121 | 6 | 5 | 500 | null | null | null | null | null | null | null | null |
drug | emugrobart | emugrobart | drug | null | 2026-06-07T07:52:44Z | null | null | Phase 2 | GDF-8 antagonist | Chugai Pharmaceutical Co Ltd | 4 | 0 | 0 | 3,938 | 1 | 1 | 0 | null | null | null | null | null | null | null | null |
drug | enicepatide | enicepatide | drug | null | 2026-06-07T07:52:47Z | null | null | Phase 3 | Gastric inhibitory polypeptide receptor agonist; Glucagon-like peptide 1 receptor agonist | Carmot Therapeutics Inc | 2 | 0 | 3 | 41 | 8 | 2 | 60 | null | null | null | null | null | null | null | null |
drug | enobosarm | enobosarm | drug | null | 2026-06-07T07:52:50Z | null | null | Phase 2 | Androgen receptor modulator | Oncternal Therapeutics Inc | 1 | 0 | 1 | 1,559 | 2 | 2 | 100 | null | null | null | null | null | null | null | null |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.